Market Minds Advisory
Calprotectin Testing Market

Calprotectin Testing Market: Point-of-Care and Home Sampling Dynamics

Rising inflammatory bowel disease incidence and clinical guidelines favoring calprotectin over invasive colonoscopy for routine monitoring are pulling testing volume toward point-of-care and home collection formats that laboratory-only providers cannot always match on convenience.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.6BMarket Size 2025
2036 FORECAST VALUE$1.6BBase Case , 2026 to 2036
CAGR 2026 TO 20369.6 %Bull 10.8% / Bear 8.3%
INCREMENTAL OPPORTUNITY$1.0BNet 10- year value creation
EXPANSION MULTIPLE2.50x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Calprotectin testing is shifting from laboratory-only ELISA workflows toward point-of-care and home sample collection formats as clinical guidelines increasingly favor this non-invasive biomarker over colonoscopy for routine inflammatory bowel disease monitoring worldwide each year. Buyers increasingly expect convenience that traditional laboratory workflows cannot always provide., particularly at major reference labs.
Point-of-care rapid calprotectin tests form the fastest-growing segment as gastroenterology clinics seek same-visit results that laboratory-based ELISA workflows cannot match on turnaround speed, while home sample collection kits gain traction among patients managing chronic disease remotely. Western Europe anchors the deepest commercial concentration, reflecting established national guideline integration and testing infrastructure, especially at leading United Kingdom and German gastroenterology centers. particularly at leading academic hospital networks.
Buhlmann and Thermo Fisher set the technology benchmark through deep clinical validation and integrated automated platforms respectively, while a fragmented tail of smaller specialty manufacturers competes on price and niche point-of-care positioning. Expanding home testing adoption and multiplex gastrointestinal panel integration are both reshaping which vendors capture testing volume as patient-driven demand grows alongside clinician-ordered volume. Smaller manufacturers increasingly form distribution partnerships to remain competitive against this pressure across the industry.
Market Definition
The calprotectin testing market covers laboratory, point-of-care, and home collection products used to measure fecal calprotectin as a biomarker for inflammatory bowel disease diagnosis, monitoring, and differentiation from irritable bowel syndrome. It spans ELISA kits, automated immunoassay platforms, lateral flow rapid tests, and home sample collection kits sold to laboratories, clinics, and patients directly. General stool culture testing and unrelated gastrointestinal biomarkers are excluded from this scope.
Base Year Value
$0.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
9.6% base case. Bull 10.8%. Bear 8.3%.
Fastest Growth Segment
Point-of-Care Rapid Calprotectin Tests: 16.2% CAGR
Fastest Growth Country
India: 12.8% CAGR
Fastest Growth Region
South Asia and Pacific: 11.9% CAGR
Largest Region
Western Europe: 28% of 2025 global value
Market Leaders
Buhlmann Laboratories, Thermo Fisher, DiaSorin, Bio-Rad Laboratories, R-Biopharm. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Calprotectin Testing Market Forecast Scenarios

calprotectin-testing-market-size-forecast-scenario-1787304335496
Calprotectin testing demand grew steadily across 2020 to 2025 as inflammatory bowel disease incidence expanded and clinical guidelines increasingly recommended the biomarker as a first-line screening tool before invasive colonoscopy referral. The market grew at an estimated 8.7% historical CAGR across the period, reflecting steady guideline-driven adoption growth alongside rising diagnosed patient volume. Emerging markets contributed an increasing share of this growth as diagnostic infrastructure expanded.
The base case assumes point-of-care testing adoption continues expanding across gastroenterology clinics through 2030, home sample collection kits gain broader payer reimbursement support, and multiplex gastrointestinal panels increasingly incorporate calprotectin alongside other biomarkers as standard practice. Together these three commercial mechanisms support a 9.6% forecast CAGR, with laboratory ELISA testing remaining the volume anchor even as point-of-care and home formats capture a growing share of total testing value each year across every major diagnostic market worldwide.
The bull case centers on faster-than-expected home testing reimbursement expansion that broadens patient access well ahead of current adoption timelines. The bear case centers on renewed laboratory budget constraints and reimbursement pressure, which would slow premium point-of-care adoption and push testing volume back toward lower-cost centralized laboratory workflows across cost-constrained health systems for several years.

Guideline Adoption and Testing Format Disruption

Calprotectin testing sits at the intersection of gastrointestinal diagnostics and chronic disease monitoring, since initial diagnostic testing typically occurs in clinical laboratory settings while ongoing disease activity monitoring increasingly moves toward point-of-care and home formats. That split has kept the vendor base divided between established laboratory diagnostics companies competing on automated platform integration and newer entrants competing on testing convenience.
TOP 5 CONCENTRATION46%share held by leading five calprotectin testing manufacturers
AVERAGE TEST PRICE$32 per testtypical price across laboratory and point-of-care test formats
LEADING COUNTRY SHAREGermany, 14%typical share of global calprotectin testing volume overall
POINT-OF-CARE ADOPTION34% of clinic testsshare of clinic-based tests using point-of-care rapid format
HOME KIT PENETRATION16% of monitoring testsshare of monitoring tests performed via home collection kits
COLONOSCOPY DEFERRAL RATE42% of low-result casestypical share of low-result cases avoiding colonoscopy referral
Commercially, the market splits between a mature laboratory ELISA base sold through established hospital and reference laboratory channels, and a smaller but faster-growing point-of-care and home tier sold on turnaround speed and patient convenience rather than price alone. Multiplex gastrointestinal panels round out demand with combined biomarker purchasing tied to broader diagnostic workup needs.
Over the next decade, testing convenience and turnaround speed will matter more than raw laboratory throughput alone, since clinicians and patients increasingly select testing formats based on how quickly results inform treatment decisions rather than which platform offers the lowest per-test cost. Vendors that can expand point-of-care and home testing access into mid-tier gastroenterology practices fastest stand to capture a widening share of a market that testing convenience is reshaping as much as clinical need is.
"This biomarker used to mean a week's wait and a lab requisition form. Now it can mean a result before the patient leaves the room, and that changes the whole referral pathway."
Director, Gastrointestinal Diagnostics Practice · MMA Healthcare / Gastrointesti

Market Trends

Point-of-Care Testing Adoption Expands Across Gastroenterology Clinics

Point-of-care rapid calprotectin testing is expanding across gastroenterology clinics as physicians seek same-visit results that inform treatment decisions without requiring patients to return for a separate follow-up appointment after laboratory processing. Buhlmann and Thermo Fisher have both expanded point-of-care platform offerings since 2023 to meet growing clinic demand, targeting practices that want faster turnaround without sacrificing quantitative accuracy comparable to laboratory ELISA testing. Smaller diagnostic laboratories are responding more slowly, constrained by the capital investment required for point-of-care platform deployment, but adoption is broadening steadily each year across major gastroenterology practices worldwide and increasingly beyond specialist settings.
Market Impact: Adds 4 million diagnosed patients g

Home Sample Collection Kits Reduce Monitoring Burden

Home sample collection kits are letting patients with established inflammatory bowel disease diagnoses monitor ongoing disease activity without frequent clinic visits, reducing the monitoring burden for both patients managing chronic disease and healthcare systems managing capacity constraints. R-Biopharm and CerTest Biotec have both expanded home collection kit availability since 2023, targeting patients who want to track disease activity between scheduled specialist appointments. This shift is letting gastroenterologists identify disease flares earlier through more frequent remote monitoring than clinic-only visit schedules previously allowed. Payers increasingly view this remote monitoring model as a meaningful cost-reduction opportunity worth supporting through expanded coverage.
Market Impact: Avoids colonoscopy in 42% of cases

Market Opportunities and Growth Drivers

Rising Inflammatory Bowel Disease Incidence Expands Testing Demand

Global inflammatory bowel disease incidence continues rising across both developed and newly industrializing markets, with the number of diagnosed Crohn's disease and ulcerative colitis patients projected to grow substantially through 2036 as diagnostic awareness and westernized dietary patterns both spread further. This incidence growth sustains long-term testing demand regardless of near-term laboratory budget cycles in any single market, providing a durable baseline growth floor beneath the faster-growing point-of-care and home testing adoption layered on top of it. Emerging markets are seeing particularly rapid incidence growth as diagnostic capability expands. Manufacturers positioning around this trend gain a stable planning foundation.
Market Impact: Limits adoption to 34% of clinics

Clinical Guidelines Increasingly Recommend Calprotectin Before Colonoscopy

National clinical guidelines in several major markets now recommend calprotectin testing as a first-line screening step before invasive colonoscopy referral for patients presenting with gastrointestinal symptoms, reducing unnecessary invasive procedures for patients whose symptoms reflect irritable bowel syndrome rather than inflammatory bowel disease. This guideline integration has expanded testing volume meaningfully since these recommendations took effect, as primary care physicians increasingly order calprotectin testing before specialist referral rather than after. Similar guideline updates are gradually spreading across additional markets as clinical evidence supporting this diagnostic pathway continues to accumulate. Manufacturers with strong guideline relationships increasingly capture this referral-driven volume first.
Market Impact: Delays adoption by 2 years

Market Restraints and Challenges

Reimbursement Variability Limits Broader Point-of-Care Adoption

Reimbursement coverage for point-of-care calprotectin testing varies considerably across health systems, with several major markets still reimbursing only laboratory-based testing at rates that make point-of-care adoption financially unattractive for many gastroenterology practices despite the clinical convenience advantages involved. This constraint is most severe in health systems where point-of-care testing carries no distinct reimbursement code separate from laboratory testing, forcing practices to absorb the cost differential themselves or forgo point-of-care adoption entirely. Manufacturers and medical societies are advocating for updated reimbursement policy to reflect point-of-care testing's clinical value, though meaningful policy change will take years across most affected markets.
Market Impact: Adds $32 per point-of-care test per

Result Interpretation Variability Creates Clinical Uncertainty

Calprotectin result interpretation varies meaningfully depending on the specific assay platform used, patient age, and testing format, creating clinical uncertainty that sometimes leads physicians to order confirmatory testing or default to more familiar laboratory ELISA methods rather than newer point-of-care alternatives. This interpretation variability is most pronounced when comparing results across different manufacturer platforms, since assay-specific calibration differences can meaningfully affect measured values for the same patient sample. Manufacturers are investing in cross-platform standardization studies and clearer clinical interpretation guidance to reduce this uncertainty, though achieving full standardization across the industry will likely take considerable additional time.
Market Impact: Cuts monitoring visits by 30% annua
3 additional market trends, 2 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Calprotectin testing products segment by testing format and platform type, the classification laboratories and clinics use to set turnaround time, pricing tier, and workflow integration, since laboratory, point-of-care, and home testing buyers each negotiate under distinct clinical terms. Vendors price each category differently depending on platform automation and testing convenience involved. Hospitals weigh both factors closely when selecting a vendor.
calprotectin-testing-market-market-share-analysis-1787304336024

Point-of-Care Rapid Calprotectin Tests

Point-of-care rapid calprotectin tests form the fastest-growing segment as gastroenterology clinics increasingly seek same-visit results that inform treatment decisions without requiring patients to return for follow-up laboratory results. Buhlmann and Thermo Fisher have both expanded point-of-care platform availability since 2023, targeting practices that want faster turnaround while maintaining quantitative accuracy comparable to laboratory testing. Clinics that adopt point-of-care testing early are capturing patient loyalty from practices still relying entirely on laboratory-based workflows, an advantage that compounds as more gastroenterologists standardize around same-visit result availability. If point-of-care adoption continues at the current pace, this segment could approach a meaningful share of total category value within the next decade. Payers increasingly view this segment as a durable long-term differentiator worth monitoring.
CAGR 16.2%

Home Sample Collection Kits

Home sample collection kits form the second-fastest segment as patients with established inflammatory bowel disease diagnoses increasingly monitor disease activity remotely rather than depending entirely on scheduled clinic visits for testing access. R-Biopharm and CerTest Biotec have both expanded home collection kit availability since 2023, targeting patients who want to track disease activity conveniently between specialist appointments. Companies that build strong home testing brand credibility early are capturing patient loyalty from laboratories that lack direct-to-patient distribution capability, an advantage that compounds as more patients discover convenient remote monitoring options. This segment increasingly serves patients seeking greater control over chronic disease management. Payers increasingly view this segment as a meaningful cost-reduction opportunity worth supporting.
CAGR 13.4%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Calprotectin testing commercial activity concentrates where clinical guideline integration and testing infrastructure are most developed, even though the underlying inflammatory bowel disease incidence driving eligible patient demand is distributed globally rather than concentrated in any particular region worldwide each year. particularly across major gastroenterology diagnostic centers worldwide.

North America

The United States accounts for the overwhelming majority of North America's calprotectin testing commercial value, reflecting dense gastroenterology specialty infrastructure, comprehensive insurance reimbursement coverage for laboratory testing, and rapidly growing point-of-care adoption at leading academic gastroenterology practices. Canada contributes a smaller but meaningful share through its established laboratory testing infrastructure, though public health system reimbursement structures have moved more cautiously on point-of-care coverage relative to the United States. Point-of-care adoption is expanding fastest here among major markets, reinforcing per-test value growth even as raw diagnosed incidence rises steadily. Home sample collection kit adoption continues broadening across major metropolitan markets each year. particularly across major United States academic gastroenterology networks nationwide.
Share: 26% | CAGR: 10.6% (2026 to 2036)

Western Europe

Germany, the United Kingdom, and France together anchor Western Europe's calprotectin testing demand, reflecting well-established national clinical guideline integration and testing infrastructure built over more than a decade of routine calprotectin adoption ahead of most other regions worldwide, which is why this region commands the largest global commercial share for this specific biomarker category. United Kingdom National Institute for Health and Care Excellence guidance has driven particularly strong primary care adoption as a pre-referral screening step before colonoscopy. Smaller Western European markets rely more heavily on centralized reference laboratories rather than distributed point-of-care testing, concentrating testing volume at fewer high-throughput sites. Regional manufacturers including Buhlmann maintain deep clinical relationships across the continent's leading gastroenterology centers.
Share: 28% | CAGR: 8.1% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
calprotectin-testing-market-country-cagr-analysis-1787304336544

Where Testing Value Concentrates Next

Revenue growth in calprotectin testing increasingly depends on capturing point-of-care adoption, home testing reimbursement expansion, and multiplex panel integration rather than raw laboratory ELISA volume alone, since testing convenience, not raw diagnosed incidence, is reshaping where testing value concentrates. The levers below outline where that value is concentrating fastest across the testing pathway today.

Expanding Point-of-Care Platform Availability Right Now

Manufacturers expanding point-of-care platform availability are capturing clinic testing volume that laboratory-only competitors cannot fulfill, particularly as more gastroenterology practices seek same-visit results for treatment decision-making. Building competitive point-of-care platform capability typically costs $12 million to $28 million in device development, clinical validation, and regulatory submission investment. Manufacturers without adequate point-of-care platforms increasingly lose clinic relationships to competitors offering faster turnaround alternatives. Manufacturers without such investment risk losing gastroenterology practice relationships to better-positioned competitors permanently over time. That advantage compounds further as more clinics standardize around faster testing turnaround. Manufacturers with adequate platforms increasingly win clinic preference over slower competitors.
Market Impact: Costs $12 to $28 million to fully b

Building Home Testing Reimbursement Advocacy Programs

Manufacturers building reimbursement advocacy programs specifically targeting home testing coverage are capturing patient volume that remains largely untapped where reimbursement policy still favors laboratory-only testing exclusively. Building competitive advocacy infrastructure typically costs $4 million to $10 million in policy engagement, clinical evidence generation, and payer relationship investment. Manufacturers with strong reimbursement positioning increasingly win home testing adoption from payers still cautious about broader coverage. Manufacturers without such positioning risk missing this reimbursement expansion wave as competitors secure favorable coverage decisions first. That advantage compounds further as more payers formalize home testing coverage policy.
Market Impact: Costs $4 to $10 million to fully bu

Securing Multiplex Gastrointestinal Panel Integration Partnerships

Manufacturers securing partnerships that integrate calprotectin into broader multiplex gastrointestinal diagnostic panels are capturing testing volume that standalone calprotectin products cannot access when laboratories prefer combined panel ordering. These partnerships typically carry a 15 to 25% margin premium over standalone testing given the bundled ordering convenience and broader diagnostic value laboratories place on combined panels. Manufacturers able to demonstrate strong panel integration performance increasingly win laboratory contracts over standalone product competitors. Manufacturers without such partnerships compete purely on standalone testing volume as panel-based ordering grows. That advantage compounds further as more laboratories consolidate around bundled panel ordering.
Market Impact: Commands a 15 to 25% margin premium

Investing In Cross-Platform Result Standardization Studies

Manufacturers investing in cross-platform result standardization studies are positioned to capture physician confidence that comparability uncertainty currently limits, since inconsistent results across different assay platforms create hesitancy about switching from familiar established testing methods. Building a competitive standardization program typically costs $3 million to $8 million in comparative study design, clinical site partnership, and publication investment. Manufacturers with published standardization data increasingly win physician trust from competitors lacking comparable cross-platform validation evidence. Manufacturers without such studies face slower adoption among comparison-sensitive clinical laboratories indefinitely. That advantage compounds further as more laboratories seek cross-platform comparability confidence.
Market Impact: Costs $3 to $8 million to fully bui

Who Controls the Margin Pool

The top five vendors hold an estimated 46% of global calprotectin testing revenue, a fragmented plurality reflecting the wide range of laboratory, point-of-care, and home testing niches spanning both established and newer diagnostic formats. Buhlmann and Thermo Fisher lead on clinical validation depth and automated platform integration respectively, while a fragmented tail of smaller specialty manufacturers competes on price and niche positioning.
Current competitive activity centers on three fronts. Point-of-care platform expansion is opening a new front for manufacturers willing to invest ahead of broader clinic adoption. Home testing reimbursement advocacy is becoming increasingly important as manufacturers compete for coverage decisions that determine broader patient access. And several mid-sized manufacturers are pursuing multiplex panel integration partnerships to differentiate beyond standalone calprotectin products.

Emerging pressure comes from smaller diagnostic technology specialists moving into point-of-care and home testing as they partner with established laboratory networks, though matching Buhlmann or Thermo Fisher's clinical validation depth remains years away for most. If these challengers close that validation gap, expect share to shift within specific regional testing markets first, before any material pressure reaches the largest incumbents given how embedded existing laboratory relationships are across the industry.
calprotectin-testing-market-company-positioning-matrix-1787304337064

Competitive Moat and Risk Dimensions

BUHLMANN LABORATORIES AG

Moat: Pioneer ELISA Clinical Validation Depth

Buhlmann pioneered commercial calprotectin ELISA testing and carries the industry's deepest clinical validation evidence base, built through decades of continuous outcomes data collection across leading European gastroenterology centers. That evidence depth gives Buhlmann a durable prescribing advantage that newer entrants without comparable clinical history cannot quickly replicate.
BUHLMANN LABORATORIES AG

Risk: Narrow Single-Category Product Focus

Buhlmann's comparatively focused calprotectin specialization means it lacks the broader diversified diagnostic revenue base that larger competitors like Thermo Fisher can draw upon to fund aggressive technology investment during periods of category-specific demand softness. If testing volume growth slows, Buhlmann faces disproportionate exposure relative to more diversified rivals.
THERMO FISHER SCIENTIFIC INC.

Moat: Broad Automated Platform Integration

Thermo Fisher integrates calprotectin testing directly into its broader automated immunoassay platform network, giving laboratories a single-vendor pathway that combines calprotectin with other routine diagnostic testing on shared equipment. That integration advantage lets Thermo Fisher capture laboratory contracts that standalone calprotectin specialists cannot match on operational efficiency.
THERMO FISHER SCIENTIFIC INC.

Risk: Premium Pricing Vulnerability To Generics

Thermo Fisher's premium-priced automated platform faces mounting pressure from lower-cost standalone calprotectin manufacturers as laboratories increasingly scrutinize per-test cost amid broader budget constraints. If price-sensitive laboratories shift toward cheaper standalone alternatives, Thermo Fisher risks losing testing volume despite its platform integration advantages. Manufacturers with strong cost discipline increasingly capture share from higher-priced integrated platform providers.

Players Tracked

Prominent Players

Buhlmann Laboratories AG
Thermo Fisher Scientific Inc.
DiaSorin S.p.A.
Bio-Rad Laboratories Inc.
R-Biopharm AG

Other Key Players

CerTest Biotec S.L.
Eagle Biosciences Inc.
Alpha Laboratories Ltd.
Inova Diagnostics Inc.
Immundiagnostik AG
Preventis GmbH
Svar Life Science AB
Genova Diagnostics Inc.
Augurix SA
BioVendor Group
Diagnostics Direct Ltd.
QuidelOrtho Corporation
Randox Laboratories Ltd.
Orgentec Diagnostika GmbH
Diasource ImmunoAssays SA

Recent Developments

MARCH 2025

Buhlmann Expands Point-of-Care Platform Manufacturing Capacity

Buhlmann commissioned additional point-of-care platform manufacturing capacity to meet rising demand from gastroenterology clinics seeking same-visit calprotectin results, following distributor commitments signed as more clinics adopted point-of-care testing. The expansion followed sustained clinical demand for faster turnaround alternatives to laboratory testing. Several other manufacturers are expected to follow.
Signal: Confirms point-of-care capacity remains th
OCTOBER 2024

Thermo Fisher Signs Multi-Year Laboratory Network Agreement

Thermo Fisher secured a multi-year testing agreement with a major regional laboratory network, guaranteeing platform integration and testing volume through 2028 across several affiliated diagnostic centers. The agreement reflects laboratories' push to lock in reliable automated testing capacity ahead of broader industry standardization. Similar agreements are expected across other competitors.
Signal: Shows laboratory networks prioritizing lon
JANUARY 2025

R-Biopharm Announces Home Testing Kit Reimbursement Milestone

R-Biopharm announced a significant reimbursement coverage decision for its home calprotectin collection kit in a major European market, expanding patient access to remote monitoring previously limited by out-of-pocket cost barriers. Similar coverage decisions are expected across other qualified markets soon. Additional coverage decisions are expected across other manufacturers soon.
Signal: Signals home testing reimbursement expansi

Antibody Reagent and Manufacturing Cost Pressure

Monoclonal antibody reagents and specialty biochemical inputs together account for roughly 34% of effective cost of goods for calprotectin testing manufacturers, given the specialized antibody production and quality control requirements involved in assay manufacturing. Point-of-care device components and packaging add a further meaningful share, particularly for manufacturers producing both laboratory and point-of-care formats. Distribution and cold-chain logistics costs round out the remaining
Antibody reagent costs rose meaningfully following 2022 global supply chain disruption, with several manufacturers reporting input cost increases exceeding 17% in their annual reports before pricing stabilized through 2023 and into 2024. Industry supply chain reviews have flagged antibody reagent sourcing as this market's single most concentrated input, more than device components or packaging costs combined. Several manufacturers have flagged reagent sourcing concentration as an ongoing operational risk.

Smaller specialty manufacturers without long-term reagent supply agreements absorbed the 2022 cost increases hardest, losing laboratory contract bids to larger competitors including Buhlmann and Thermo Fisher that had negotiated priority supplier allocation years in advance. Manufacturers with secured reagent supply weathered the cost increases far better than those dependent on spot market purchasing, a cost advantage that persists most sharply across smaller specialty manufacturers today.
calprotectin-testing-market-cost-volatility-analysis-1787304337258

Long-Term Reagent Supplier Agreements Secure Pricing

Manufacturers increasingly negotiate multi-year antibody reagent supply agreements with priority allocation clauses, reducing exposure to spot market price volatility during periods of global supply chain disruption. This approach has helped several manufacturers maintain more stable testing pricing even during periods of broader input cost inflation across the industry. This approach is becoming increasingly standard practice across the broader industry today.

Shared Manufacturing Infrastructure Lowers Fixed Cost

Smaller specialty manufacturers increasingly share antibody production and assay manufacturing infrastructure through partnership arrangements, spreading fixed equipment cost across broader production volume than any single smaller operation could support alone economically. This shared infrastructure model has helped smaller players remain price-competitive against larger integrated manufacturers. This model has become increasingly common as smaller manufacturers scale operations without heavy capital investment.

Vertical Integration Into Antibody Production Reduces Exposure

Several larger manufacturers are investing in direct antibody production capability to reduce dependence on third-party reagent suppliers, gaining pricing control and supply security that non-integrated competitors cannot match during periods of tightening capacity. This integration also reduces exposure to spot market volatility across the supply chain. This has helped several companies weather recent volatility better.

Portfolio Architecture for Margin Defence

Calprotectin testing portfolios span three margin tiers, from commodity-adjacent laboratory ELISA kits sold largely on price, through certified automated immunoassay platforms carrying integration-driven premiums, toward an emerging next-generation tier built around point-of-care and home testing formats still gaining share. Gross margin widens meaningfully at each tier as testing convenience and platform integration increase across the industry today, reflecting growing willingness to pay for t
The volume versus premium tension centers on platform and reimbursement investment allocation. Manufacturers must choose between dedicating capital to high-margin point-of-care and home testing programs with growing but still-smaller volume, or serving reliable laboratory ELISA demand that fills out most testing volume across a typical year. Manufacturers without spare capital increasingly favor higher-margin next-generation programs where competition remains comparatively thin still.

High-value margin pools concentrate in point-of-care and home testing formats, where platform investment and reimbursement advocacy keep competition thin and clinicians pay a premium for turnaround speed and patient convenience. Laboratory ELISA testing remains the volume anchor but carries thinner margins across the portfolio, leaving smaller manufacturers with fewer diversification options than larger integrated competitors today. This concentration should persist while reimbursement access remains uneven.

Volume / Commodity-Adjacent Tier

Laboratory ELISA calprotectin kits sold largely on price and laboratory contract relationships without integration-driven premiums, across most standard diagnostic buyer segments worldwide each year. Pricing pressure from laboratory purchasing committees keeps margins comparatively thin across this tier overall.
Gross Margin: 26-36%

Premium / Certified Tier

Automated chemiluminescent immunoassay platforms sold under laboratory network contracts carrying integration-driven pricing power built through years of proven testing performance across major networks worldwide. Laboratories increasingly compare platform performance data before committing to a long-term relationship.
Gross Margin: 38-48%

Sustainability / Regulatory / Next-Generation Tier

Point-of-care and home testing formats in active clinic and patient adoption, commanding premium pricing against limited proven alternatives as convenience and reimbursement access expand across major markets. Manufacturers with the deepest platform and reimbursement capability capture most of this premium value.
Gross Margin: 46-58%
calprotectin-testing-market-portfolio-architecture-1787304337758

Recurring Monitoring Purchasing Pattern

Calprotectin testing purchasing functions closer to a recurring annuity than a single transaction for patients with confirmed inflammatory bowel disease diagnoses, since disease activity monitoring typically continues indefinitely across the patient's ongoing treatment relationship rather than following any defined testing endpoint. Initial diagnostic testing behaves differently, occurring as a single screening step before diagnosis confirmation and subsequent treatment pathway determination.
Adoption depth varies sharply by end-use vertical. Academic gastroenterology centers and specialty inflammatory bowel disease clinics show the deepest engagement with point-of-care and home testing formats, given dedicated care coordination resources and patient population comfort with newer testing technology, while primary care settings adopt more slowly since testing volume rarely justifies dedicated point-of-care equipment investment. That divide shapes where manufacturers concentrate commercial investment.

A generational shift is underway as younger gastroenterologists, trained during the era of routine point-of-care and home testing availability, evaluate testing manufacturers on convenience and turnaround speed rather than decades-long familiarity with laboratory-only ELISA workflows. That openness gives convenience-forward manufacturers a rare opening to win clinic share in a category where legacy laboratory relationships have otherwise been difficult to dislodge, across several major diagnostic markets today.
calprotectin-testing-market-end-use-penetration-index-1787304338246

Where MMA Sees The Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / POINT-OF-CARE PLATFORM INVESTMENT

Expand Point-of-Care Capability Before Clinic Demand Peaks

Gastroenterology clinics are increasingly requiring same-visit results before adopting a manufacturer as their primary testing partner, and manufacturers without adequate point-of-care investment are losing clinic relationships to better-equipped competitors as this shift accelerates. Platform investment requires meaningful upfront capital but opens durable clinic relationships that laboratory-only competitors cannot match once turnaround speed fully matters. Manufacturers waiting until clinic demand fully peaks will find themselves racing to catch up against incumbents who invested years earlier, a gap that widens each quarter platform investment lags behind competitor programs already underway.
02 / HOME TESTING REIMBURSEMENT ACCESS

Fund Reimbursement Advocacy Before Coverage Policy Settles

Payers have not universally committed to covering home calprotectin testing, leaving a genuine opportunity for manufacturers willing to fund advocacy and evidence generation ahead of confirmed broader coverage trends. Waiting for reimbursement policy to formally settle risks missing the coverage expansion window entirely once payers finalize their preferred testing coverage frameworks. The investment required is meaningful but positions early movers to capture a testing category growing faster than laboratory-only testing today, a window that will not stay open indefinitely once coverage policy fully settles.
03 / PANEL INTEGRATION PARTNERSHIPS

Pursue Multiplex Panel Integration Before Bundling Standardizes

Laboratories increasingly prefer bundled multiplex gastrointestinal panel ordering over standalone calprotectin testing, and manufacturers without dedicated integration partnerships risk ceding this growing ordering pattern to competitors who invest in panel relationships earlier. Panel integration represents a meaningful differentiation opportunity even though standalone testing currently drives most category revenue. Manufacturers pursuing integration partnerships now, while competitive density remains manageable, protect testing volume against the next wave of competitors entering this category as bundled ordering continues to grow across major laboratory networks nationwide.
04 / REGIONAL ACCESS INVESTMENT

Prioritize South Asia and East Asia Access Investment

South Asia and Pacific and East Asia carry rapidly growing diagnosed inflammatory bowel disease populations relative to their current commercial calprotectin testing value, as diagnostic infrastructure investment accelerates across India, China, and neighboring markets. Manufacturers concentrating capacity expansion solely around legacy Western European laboratory relationships risk ceding share in the regions where testing volume growth will be steepest through 2036. Early investment in regional diagnostic and distribution partnerships offers a meaningful head start over competitors still anchored entirely to legacy Western customer bases.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Calprotectin Testing Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Calprotectin Testing Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized gastroenterology practice network operating multiple clinic locations across a major United States metropolitan area, managing several thousand inflammatory bowel disease patients across its affiliated practices. The network reported annual clinical services revenue of approximately $68 million (client-reported, unverified by MMA) and was evaluating whether to invest in in-house point-of-care testing capability or continue relying entirely on external laboratory services instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether building in-house point-of-care testing capability, which required capital investment and staff training, would generate sufficient patient satisfaction and workflow efficiency gains to justify the cost relative to continuing external laboratory reliance. Competing practice networks were beginning to adopt point-of-care testing regionally, raising competitive pressure. Delaying the decision risked ceding ground to competing regional practices.
MMA APPROACH
MMA benchmarked the client's projected testing volume against comparable gastroenterology practices that had already adopted point-of-care testing, modeling patient satisfaction and workflow efficiency gains against capital and training investment requirements. The analysis incorporated primary survey data from practice administrators at nine comparable regional networks. Findings were cross-checked against patient satisfaction benchmarks published in recent healthcare industry surveys.
KEY FINDINGS
  1. Patient satisfaction scores improved more than management initially expected once same-visit result availability was properly incorporated into the practice experience evaluation model used.
  2. Peer practice networks that adopted point-of-care testing reported measurably faster treatment decision timelines than networks relying entirely on external laboratory turnaround schedules.
  3. Workflow efficiency gains from reduced follow-up appointment scheduling offset a meaningful share of the equipment investment required, though timing depended on patient volume.
  4. Continuing external laboratory reliance carried a quantifiable competitive risk as patients increasingly viewed same-visit testing as a marker of overall practice quality and modernity.
CLIENT PROFILE
The client is a mid-sized gastroenterology practice network operating multiple clinic locations across a major United States metropolitan area, managing several thousand inflammatory bowel disease patients across its affiliated practices. The network reported annual clinical services revenue of approximately $68 million (client-reported, unverified by MMA) and was evaluating whether to invest in in-house point-of-care testing capability or continue relying entirely on external laboratory services instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether building in-house point-of-care testing capability, which required capital investment and staff training, would generate sufficient patient satisfaction and workflow efficiency gains to justify the cost relative to continuing external laboratory reliance. Competing practice networks were beginning to adopt point-of-care testing regionally, raising competitive pressure. Delaying the decision risked ceding ground to competing regional practices.
MMA APPROACH
MMA benchmarked the client's projected testing volume against comparable gastroenterology practices that had already adopted point-of-care testing, modeling patient satisfaction and workflow efficiency gains against capital and training investment requirements. The analysis incorporated primary survey data from practice administrators at nine comparable regional networks. Findings were cross-checked against patient satisfaction benchmarks published in recent healthcare industry surveys.
KEY FINDINGS
  1. Patient satisfaction scores improved more than management initially expected once same-visit result availability was properly incorporated into the practice experience evaluation model used.
  2. Peer practice networks that adopted point-of-care testing reported measurably faster treatment decision timelines than networks relying entirely on external laboratory turnaround schedules.
  3. Workflow efficiency gains from reduced follow-up appointment scheduling offset a meaningful share of the equipment investment required, though timing depended on patient volume.
  4. Continuing external laboratory reliance carried a quantifiable competitive risk as patients increasingly viewed same-visit testing as a marker of overall practice quality and modernity.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 5): Evaluate point-of-care platform vendors and begin staff training ahead of formal equipment deployment across pilot locations. Phase 2: Phase 2 (Months 6 to 13): Deploy point-of-care testing capability across all clinic locations while tracking patient satisfaction and workflow efficiency closely. Phase 3: Phase 3 (Months 14 to 22): Expand point-of-care capability to support broader regional referral partnerships once initial performance confirms sustained operational benefits.
OUTCOME
Within eighteen months of deployment, the client reported patient satisfaction score improvement of approximately 22% (client-reported, unverified by MMA), exceeding initial projections meaningfully. Treatment decision timelines shortened measurably (client-reported, unverified by MMA), and the network now serves as a regional reference site for smaller gastroenterology practices.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Calprotectin Testing Market?

The global calprotectin testing market was valued at approximately $0.58 billion in 2025. Growth is driven primarily by rising inflammatory bowel disease incidence and expanding point-of-care adoption.

How large will the Calprotectin Testing Market be by 2036?

The market is forecast to reach approximately $1.60 billion by 2036, roughly 2.50 times its 2026 value as point-of-care and home testing formats broaden globally.

What is the CAGR for the Calprotectin Testing Market 2026 to 2036?

The market is forecast to grow at a 9.6% CAGR between 2026 and 2036. Bull and bear scenarios range from roughly 8.3% to 10.8% depending on reimbursement and guideline adoption trends.

Which segment is growing fastest?

Point-of-care rapid calprotectin tests are the fastest-growing segment at approximately 16.2% CAGR, roughly 1.69 times the overall market growth rate. Home sample collection kits follow as the second-fastest segment.

Who are the major companies in the Calprotectin Testing Market?

Leading companies include Buhlmann Laboratories, Thermo Fisher, DiaSorin, Bio-Rad Laboratories, and R-Biopharm, together holding an estimated 46% of global commercial revenue. Smaller specialty manufacturers make up the remaining share.

Which country is growing fastest?

India is the fastest-growing country at approximately 12.8% CAGR, driven by rising inflammatory bowel disease incidence and improving diagnostic infrastructure. Germany still commands the largest overall share of commercial value.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Testing Format and Platform Type

  • Laboratory-Based ELISA Calprotectin Tests
  • Point-of-Care Rapid Calprotectin Tests
  • Home Sample Collection Kits
  • Automated Chemiluminescent Immunoassay Analyzers
  • Quantitative Lateral Flow Reader Systems
  • Multiplex Gastrointestinal Panel Testing

By End-Use Testing Setting

  • Academic Gastroenterology Centers
  • Community Gastroenterology Clinics
  • Reference and Hospital Laboratories
  • Direct-to-Patient Home Testing

By Commercial Dimension

  • Diagnostic Screening Testing
  • Ongoing Disease Monitoring Testing
  • Laboratory Contract Purchasing
  • Direct-to-Consumer Distribution Channels

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The calprotectin testing market covers laboratory, point-of-care, and home collection products used to measure fecal calprotectin as a biomarker for inflammatory bowel disease diagnosis, monitoring, and differentiation from irritable bowel syndrome. It spans ELISA kits, automated immunoassay platforms, lateral flow rapid tests, and home sample collection kits sold to laboratories, clinics, and patients directly. General stool culture testing and unrelated gastrointestinal biomarkers are excluded from this scope.
Quantitative Units
USD billions (current prices); test volume in millions where applicable
Segmentation Dimensions
By Testing Format and Platform Type; By End-Use Testing Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Buhlmann Laboratories AG, Thermo Fisher Scientific Inc., DiaSorin S.p.A., Bio-Rad Laboratories Inc., R-Biopharm AG, CerTest Biotec S.L., Eagle Biosciences Inc., Alpha Laboratories Ltd., Inova Diagnostics Inc., Immundiagnostik AG, Preventis GmbH, Svar Life Science AB, Genova Diagnostics Inc., Augurix SA, BioVendor Group, Diagnostics Direct Ltd., QuidelOrtho Corporation, Randox Laboratories Ltd., Orgentec Diagnostika GmbH, Diasource ImmunoAssays SA
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-163
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Calprotectin Testing Market Report (2026 to 2036).

This report provides a comprehensive analysis of the global calprotectin testing market, covering laboratory, point-of-care, and home testing segments across all seven MMA-tracked global regions. It includes detailed market sizing and forecasts through 2036, competitive benchmarking of the top twenty vendors across established and emerging diagnostic companies, and segment-level analysis of testing format adoption. The report draws on MMA's primary survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025, supplemented by company disclosures and government health agency data. Buyers receive full access to regional data tables, competitive profiles, and strategic recommendations tailored to diagnostic manufacturers, laboratory networks, and healthcare investors worldwide.
Full seven-region market sizing and forecast data
Competitive benchmarking of twenty profiled industry vendors
Segment-level analysis of testing format adoption trends
Primary survey data from 3,800 global respondents
Expert interview insights from 47 gastroenterology specialists
Strategic recommendations for diagnostic manufacturers and laboratories

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts